Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SOBR pops up as a buy signal from my SO (sell off) strategy). Lots of rules behind that strategy, hence an SO signal is rare for me. I'm in and up 10% at the moment.
So, maybe we'll learn something tomorrow.
GENEVA, SWITZERLAND / ACCESSWIRE / October 26, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), today announced that they and NRx Pharmaceuticals, Inc. ("NRx") have agreed to extend the stay of their pending litigation until November 7, 2022 to allow time for the parties to finalize their tentative litigation settlement. There can be no assurance that the parties will successfully complete their proposed settlement.
Again, the FDA doesn't care squat about the secondary endpoint if the primary fails. So the design of the primary endpoint criteria is critical for success. It's a simple concept to grasp.
No spin will change those facts.
That's exactly with relief did. As the virus evolved and SOC evolved, the FDA permitted them to change the parameters surrounding their primary endpoints. So the situation is similar in that respect. The general thinking (arm chair quarterbacking) is the primary endpoints were too rigid, and the secondary endpoint should have been the primary endpoint.... because there was success with the secondary endpoint. It's all about endpoint design, and 'getting it right'.
Regarding the NIH study and aviptadil, you are incorrect regarding the secondary endpoint. Here is an excerpt...
In this multicenter, randomized, placebo-controlled trial among critically ill patients with COVID-19 and respiratory failure, we did not reach statistical significance (OR, 1.6; 95% CI, 0.86–3.11) on the primary end point of being alive and free of respiratory failure at 60 days. There was a two-fold, statistically significant increased odds of day 60 survival (the key secondary end point) (p = 0.035).
Full study results....
https://journals.lww.com/ccmjournal/Fulltext/2022/11000/The_Use_of_IV_Vasoactive_Intestinal_Peptide.1.aspx?fbclid=IwAR0_feyIsWpE0jFpZASAjg_q5hJxVIT5GApgUYJ5_dqrJODYb8uat4s-RGc
So, why the 6 day down slide in price? What has accounted for that pull back?
Well let's hope that mf gets it right this time. This is precisely what tripped up RLFTF. They redid the primary endpoint towards the end of the P3 trial. The FDA approved it. But in the end they still did not 100% meet the 'primary' endpoint, even though they performed very will with the 'secondary' endpoints. The FDA rejected them because they missed the primary. The FDA could care less about the secondary endpoints even though the secondary can demonstrate great safety and efficacy.
This is very risky business when you are working with the FDA. I've always felt that Congress should appoint an oversight committee to ensure that the FDA key decision makers are 1) competent 2) not corrupt. IMO the lucrative PDUFA fees seriously bias (and corrupt) the FDA in their decision making. Last year Project Veritas recorded an undercover video/audio with an FDA decision maker which brought a lot of this to light. It is what it is.
FDA EUA approval is 100% linked to meeting the 'Primary Endpoints'. Absolutely NOTHING else matters.... no matter how good it is!!! Gotta meet the 'Primary Endpoints', or the FDA will reject it. This is exactly what happened to other promising small biotechs during the pandemic.
So the entire success or failure hinges on how well thought out the design of the "endpoints" are. Secondary endpoints do not matter.
You have me curious now. How will they pay the price?
No, that is not what I am saying. What I am saying is I have better things to do with my time than to grieve all day and night over this. Try to look for a silver lining. Maybe ....... learn from your mistakes in trading risky penny stocks.
Not anymore. Why would they. It serves to purpose anymore.
What's a bit puzzling is the float is still relatively low at 114,918,316.
At a half a billion shares O/S, this thing is ripe for an R/S. Unfortunately.
And how will that happen? I'm sure they stopped reading this board a long time ago.
What is the purpose of this? What does this hope to accomplish? What is the objective? The purpose?
Business as Usual. Just a negotiating strategy by the unions and management. Pilots what huge pay raises. They've been negotiating this contract agreement for 3 years. American Airlines expects to see record sales over the upcoming holidays.
govs... I'm optimistic that we'll see .22 again. And we'll see .17 again too. Great for swing trading.
Well ReviveThomas ... how did your prediction work out for you. Weeks? That prediction was in Jan 2022. As I've said many times, this is a great stock for swing trading! Long term, it will most likely turn out to be a covid19 flop just like the rest of the small biotechs with big promises. Mostly because M.F. has been in love with shrooms right from the get go. Even if this drugs works, it's too little too late. In the meantime, I'm still swinging away! JMHO.
I must admit though that the new 15c2-11 ruling has muddied the waters a bit. I'm not sure if the SEC delisting policy includes the expert market or not. But in the grand scheme of things it's a moot point if someone is trying to sell their shares when there is virtually no volume.
Sorry, that will never happen. 2 years from now this ticker will most likely be hanging around attracting newcomers look for a new opportunity. The incumbent SH will be long gone. That's how it works in penny world. Tickers just don't disappear overnight unless there is a change of some sort initiated by the insiders. The SEC doesn't go around shutting down penny stocks. They simply do not have the resources for that. If you make an inquiry with them, they usually just say.... "Buyers Beware with penny stocks". They have no sympathy for SH who are looking for get rich quick penny stocks.
Mountain... not very much at all (compared to you). So I understand why you are frustrated. Considering how low the float and o/s were (once upon a time), I'm surprised that mgmt got so easily derailed by not being able to process simple paperwork. This stock had a lot of promise IMO. Clearly, we do not know the full story regarding what happened. We may never know.
pegs...where are you seeing RLFTF stating that they are in Phase 2 trials with aviptadil? Are you referring to the inhaler trial?
We are waiting for the NIH to release the data on that puzzling trial.
We are also getting close for the results from the Dr. Jörg Leuppi inhaler phase 2 trial (Dec 2022). It says 82 patients, but I'm pretty sure they have increased that size to 132 patients.
Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS
https://clinicaltrials.gov/ct2/show/NCT04536350
As an innocent person, I would never want you on my jury. Innocent until proven guilty pertains to all.
My home handy man's name is Tom Nelson (I'm not kidding).
10/10/22 - Relief Announces U.S. Launch of PKU GOLIKE
https://relieftherapeutics.com/newsblog-detail/?newsID=2357931
Jedi... wow, you hit that one at the bullseye!!! The FDA did indeed throw a major curve ball at QNTA.
I've always been of the opinion that the President should appoint an independent 'oversight' team over the FDA decision makers to help weed out incompetence and corruption.
There is ample evidence that there is sizable corruption via the PDFA (act). On the $ take! Particularly with big pharma.
And considering the high volume of FDA drug recalls (due to safety), there is also ample evidence of incompetence IMO. Last year one of the key FDA decision makers resigned because his FDA team approved an Alzheimer's drug that missed it's primary endpoints and showed very little efficacy. He was so disgusted that he walked off. My guess is the lucrative PDFU fees enticed them into approving it.
Shoondale... would you please post specific, concrete evidence that you have in your possession that proves (without a doubt) that QNTA scammed their investors. Missing SEC filing dates does not qualify as a scam. And speculating by trying to read between the lines on a financial statement does not count either. Please post concrete PROOF that they are a scam by including specific links or SEC / law enforcement phone numbers who will testify that QNTA is a scam. Thank you in advance.
Mountain.. I have to strongly agree with you on this point. They should issue a PR providing the SH with an update as well as their future plans. They can always state that they are not at liberty to comment on the SEC investigation. However, they should at least provide an update on business operations and their future plans.
Is it possible that the SEC placed a gag order on them? I would not think so.
Maybe they will read my post.
Copy That!
In at .16, out at .22 37% ROI. Very nice.
It's not so obvious to many. I highly suspect that you are betting your farm on this one. Like many others. Lot of headstones scattered about in penny land. Possibly RVVTF will be different. The probabilities say that it won't be any different. Yes, I've been around here for quite a while... swing trading this puppy.
Rick..yes, like I did with RLFTF. Diversify. Don't put all of your eggs in one basket. RLFTF is a great example of everyone having extremely high hopes, only to be dashed by trials that did not meet expectation.
mrpenny...RVVTF is a very good stock for swing trading though. Whether the true longs get rewarded over the long term is anyone's guess. And true longs that are putting all of their eggs in one basket is a very bad, risky move though. To each his/her own though. JMHO
pegs, I have no crystal ball. But I was hoping that ACER would have been ready for it's June 5 PDUFA event, but they weren't. So that is pushed off to mid January 2023. If the FDA approves their drug then that would generate a revenue stream for RLFTF which should give the pps a small boost.
NASDAQ...I'm still convinced that RAM is doing the ADR so that he will have another mechanism to dilute (by selling ADRs). He must wait until Level 3 is reached though before he can dilute like that. The big question for me is..... what impact will diluting per ADR selling have on the underlying stock (RLFTF)? Just don't know. But if we are forced to convert our OTC shares to ADR, then it is a moot point. We will then be at the mercy of the NASDAQ market place with the ADRs. Even if there is no RAM driven ADR dilution, then IMO we will still need a positive stream of good news being PR'd to sustain the new higher (150x) pps on the NASDAQ. And RAM may surprise us with a 250x conversion.
Obtuse... I can't disagree with any of your assessment. As you may know, the PDUFA (act) allows the FDA to collect massive $ fees from drug makers as they sell their drugs. So there is a corrupt incentive for the FDA to approve drugs that will provide them with maximum kickback $$ fees. PDUFA was supposed to accelerate the FDA approval process to more quickly put life saving drugs into the hands of the consumer. Instead..... PDUFA has provided a revenue generating vehicle that the FDA has exploited. Big Pharma clearly has the edge for approvals ...thanks to PDFUA. PDUFA should be killed IMO.
Mountain.. no one is justifying their actions. The problem is --- there is nothing we can do. So I am not going to grieve over it. If QNTA can pull a rabbit out of their hat by securing a deal with some partner, then that would be great. Else... my whole life does not revolve around QNTA. And nagging the SEC to crush QNTA will serve no useful purpose for the the incumbent shareholders.
BTW, the SEC is not going to put anyone in jail. The SEC will simply tell you to never put your hard earned $$ into a risky, unproven penny stock. And they don't have the resources to chase down every penny stock scam on the OTC. So that will never happen. Rather the SEC states.... "Buyers Beware".
Diversification is the key to surviving investments in penny stocks. The vast majority are losers, but occasionally you get a big winner.
Mrpenny.... recent events certainly cast some very dark shawdows! Tiny biotechs tend to be very volatile, and they die a very slow death with the investor pain lingering for several years. However, I'm not quite there yet with RVVTF. They are trying to navigate new FDA hurdles, and we'll see how effective they can do that. RLFTF was unsuccessful with navigating those FDA hurdles and that stock pps finally tanked.
There is still some hope left for RVVTF IMO. But as I've posted many times, I don't believe MIchael Frank is very effective at driving this boat, and he's had his priorities all screwed up from the very beginning IMO. He's a shroom guy. Several years ago I also discovered that Michael has been associated with performing a R/S with another company. So as the O/S and float grow with RVVTF, I do fear he'll eventually resort to that as a means to help raise funds. Time will tell.
Jedi.. you bring up some very good points (cost of RE in CA, working from home, etc). The landscaping looks pretty well kept as well. It's a non-issue IMO.
You will only shoot yourself in the foot by encouraging the SEC to delist QNTA.
Mountain ... why would you encourage the SEC to delist QNTA? Wouldn't that result in your losing all of your equity for sure?
Buy now at .18, sell at .26 sometime over the next 20-30 days = 44% ROI. That's nice by any standard. That's not flipping. That's a form of swing trading.